Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model

Neuroscience Letters

Volumn 580, Issue , 2014, Pages 119-124

  Kanbara, Tomoe ^a,b   Nakamura, Atsushi ^a,b   Shibasaki, Masahiro ^b   Mori, Tomohisa ^b   Suzuki, Tsutomu ^b   Sakaguchi, Gaku ^a   Kanemasa, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Antinociception; MOR agonists; Neuropathy; Oxaliplatin

Indexed keywords

FENTANYL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; MORPHINE; OXALIPLATIN; OXYCODONE; POTASSIUM CHANNEL BLOCKING AGENT; TERTIAPIN Q; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PLATINUM COMPLEX;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; TREATMENT DURATION; AGONISTS; ANIMAL; METABOLISM; NEURALGIA; SPRAGUE DAWLEY RAT;

ANALGESICS, OPIOID; ANIMALS; ANTINEOPLASTIC AGENTS; FENTANYL; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; MALE; MORPHINE; NEURALGIA; ORGANOPLATINUM COMPOUNDS; OXYCODONE; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 84906485888     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.08.005     Document Type: Article

References (38)

1. Moulin D.E., Iezzi A., Amireh R., Sharpe W.K., Boyd D., Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996, 347(8995):43-47.
2. Nelson K.A., Glare P.A., Walsh D., Groh E.S. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J. Pain Symptom Manage. 1997, 13(5):62-67.
3. Koyyalagunta D., Bruera E., Solanki D.R., Nouri K.H., Burton A.W., Toro M.P., Bruel B.M., Manchikanti L. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012, 15(3 Suppl.):ES39-ES58.
4. Minami K., Hasegawa M., Ito H., Nakamura A., Tomii T., Matsumoto M., Orita S., Matsushima S., Miyoshi T., Masuno K., Torii M., Koike K., Shimada S., Kanemasa T., Kihara T., Narita M., Suzuki T., Kato A. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J. Pharmacol. Sci. 2009, 111(1):60-72.
5. Nakamura A., Hasegawa M., Minami K., Kanbara T., Tomii T., Nishiyori A., Narita M., Suzuki T., Kato A. Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br. J. Pharmacol. 2013, 168(2):75-88.
6. Kuo A., Wyse B.D., Meutermans W., Smith M.T. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. Br. J. Pharmacol. 2014, (in press).
7. Marker C.L., Luján R., Loh H.H., Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J. Neurosci. 2005, 25(14):551-559.
8. González-Rodríguez S., Hidalgo A., Baamonde A., Menéndez L. Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 2010, 381(1):59-71.
9. Nakamura A., Fujita M., Ono H., Hongo Y., Kanbara T., Ogawa K., Morioka M., Nishiyori A., Shibasaki M., Mori T., Suzuki T., Sakaguchi G., Kato A., Hasegawa M. G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites. Br. J. Pharmacol. 2014, 171(1):53-64.
10. Ali B.H. Ameliration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin. Pharmacol. Toxicol. 2010, 106(4):272-279.
11. Saif M.W., Syrigos K., Kaley K., Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010, 30(7):2927-2933.
12. Nagashima M., Ooshiro M., Moriyama A., Sugishita Y., Kadoya K., Sato A., Kitahara T., Takagi R., Urita T., Yoshida Y., Tanaka H., Oshiro T., Okazumi S., Katoh R. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support. Care Cancer 2014, 22(6):1579-1584.
13. Kanbara T, Nakamura A, Takasu K, Ogawa K, Shibasaki M, Mori T, Suzuki T, Hasegawa M, Sakaguchi G, Kanemasa T. The contribution of Gi/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model. (Unpublished results).
14. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, San Diego. sixth ed.
15. Narita M., Nakamura A., Ozaki M., Imai S., Miyoshi K., Suzuki M., Suzuki T. Comparative pharmacological Profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 2008, 33:1097-1112.
16. + channels. Biochemistry 1998, 37(38):3291-3299.
17. Nakamura A., Hasegawa M., Ito H., Minami K., Koike K., Habu-Tomita N., Nanba K., Hamaguchi K., Noshi E., Hashimoto H., Nishino I., Okabayashi Y., Koyabu K., Kihara T., Iwamoto Y., Inoue Y., Narita M., Suzuki T., Kato A. Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. J. Pain Palliat. Care Pharmacother. 2011, 25:318-334.
18. Bhargava H.N., Larsen A.K., Rahmani N.H., Villar V.M. Naltrexone-induced alterations of the distribution of morphine in brain regions and spinal cord of the rat. Brain. Res. 1993, 607(1-2):1-8.
19. Hoekman J.D., Ho R.J. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth. Analg. 2011, 113(3):41-51.
20. Pöyhiä R., Kalso E.A. Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol. Toxicol. 1992, 70(2):25-30.
21. Sharon D., Vorobiov D., Dascal N. Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes. J. Gen. Physiol. 1997, 109:477-490.
22. Narita M., Mizuo K., Shibasaki M., Narita M., Suzuki T. Up-regulation of the G(q/11alpha) protein and protein kinase C during the development of sensitization to morphine-induced hyperlocomotion. Neuroscience 2002, 111:127-132.
23. Psigfogeorgou K., Terzi D., Papachatzaki M.M., Varidaki A., Ferguson D., Gold S.J., Zachariou V. A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. J. Neurosci. 2011, 13:5617-5624.
24. Chen Y.P., Chen S.R., Pan H.L. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J. Pharmacol. Exp. Ther. 2005, 314(2):611-617.
25. Chen S.R., Pan H.L. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids. Brain Res. 2006, 1081(1):19-25.
26. Levy R.A., Proudfit H.K. Analgesia produced by microinjection of baclofen and morphine at brain stem sites. Eur. J. Pharmacol. 1979, 15((57)1):43-55.
27. Urban M.O., Smith D.J. Nuclei within the rostral ventromedial medulla mediating morphine antinociception from the periaqueductal gray. Brain Res. 1994, 25((652)1):9-16.
28. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 1984, 7:309-338.
29. Reichling D.B., Kwiat G.C., Basbaum A.I. Anatomy, physiology and pharmacology of the periaqueductal gray contribution to antinociceptive controls. Prog. Brain Res. 1988, 77:31-46.
30. Hahm E.T., Kim Y., Lee J.J., Cho Y.W. GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain. BMC Neurosci. 2011, 12:41.
31. Takasu K, Ogawa K, Nakamura A, Kanbara T, Tomii T, Morioka Y, Hasegawa M, Shibasaki M, Mori T, Suzuki T, Sakaguchi G. Enhanced GABAergic synaptic transmission in VLPAG neurons and potent modulation by oxycodone in a chronic bone cancer pain model. (Unpublished results).
32. Han M.H., Renthal W., Ring R.H., Rahman Z., Psifogeorgou K., Howland D., Birnbaum S., Young K., Neve R., Nestler E.J., Zachariou V. Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol. Psychiatry 2010, 67(8):61-69.
33. Celver J., Xu M., Jin W., Lowe J., Chavkin C. Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol. Pharmacol. 2004, 65(3):28-37.
34. Koch T., Widera A., Bartzsch K., Schulz S., Brandenburg L.O., Wundrack N., Beyer A., Grecksch G., Höllt V. Receptor endocytosis counteracts the development of opioid tolerance. Mol. Pharmacol. 2005, 67(1):80-87.
35. Sternini C., Spann M., Anton B., Keith D.E., Bunnett N.W., von Zastrow M., Evans C., Brecha N.C. Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc. Nat. Acad. Sci. U.S.A. 1996, 93(17):9241-9246.
36. Zheng H., Loh H.H., Law P.Y. Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol. Pharmacol. 2008, 73(1):178-190.
37. Imai S., Narita M., Hashimoto S., Nakamura A., Miyoshi K., Nozaki H., Hareyama N., Takagi T., Suzuki M., Narita M., Suzuki T. Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain. Nihon Shinkei Seishin Yakurigaku Zasshi 2006, 26(5-6):183-192.
38. Narita M., Imai S., Nakamura A., Ozeki A., Asato M., Rahmadi M., Sudo Y., Hojo M., Uezono Y., Devi L.A., Kuzumaki N., Suzuki T. Possible involvement of prolonging spinal μ-opioid receptor desensitization in the development of antihyperalgesic tolerance to μ-opioids under a neuropathic pain-like state. Addict. Biol. 2013, 18(4):14-22.